Immunotherapy and biomarkers in patients with lung cancer with tuberculosis: Recent advances and future Directions

Ling Yang; Li Zhuang; Zhaoyang Ye; Linsheng Li; Jingzhi Guan; Wenping Gong

doi:10.1016/j.isci.2023.107881

Immunotherapy and biomarkers in patients with lung cancer with tuberculosis: Recent advances and future Directions

iScience. 2023 Sep 12;26(10):107881. doi: 10.1016/j.isci.2023.107881. eCollection 2023 Oct 20.

Authors

Ling Yang^{1

2

3}, Li Zhuang², Zhaoyang Ye², Linsheng Li², Jingzhi Guan³, Wenping Gong¹

Affiliations

¹ Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Senior Department of Tuberculosis, Eighth Medical Center of PLA General Hospital, Beijing 100091, China.
² Hebei North University, Zhangjiakou, Hebei 075000, China.
³ Senior Department of Oncology, Fifth Medical Center of PLA General Hospital, Beijing 100071, China.

Abstract

Lung cancer (LC) and tuberculosis (TB) are two major global public health problems, and the incidence of LC-TB is currently on the rise. Therefore effective clinical interventions are crucial for LC-TB. The aim of this review is to provide up-to-date information on the immunological profile and therapeutic biomarkers in patients with LC-TB. We discuss the immune mechanisms involved, including the immune checkpoints that play an important role in the treatment of patients with LC-TB. In addition, we explore the susceptibility of patients with LC to TB and summarise the latest research on LC-TB. Finally, we discuss future prospects in this field, including the identification of potential targets for immune intervention. In conclusion, this review provides important insights into the complex relationship between LC and TB and highlights new advances in the detection and treatment of both diseases.

Keywords: Cancer; Immunology; Microbiology.

Publication types

Review